NCT07216560View on ClinicalTrials.gov

First-in-human Study of 7MW4911 in GI Cancer

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

200

Participants

Timeline

Start Date

November 30, 2025

Primary Completion Date

July 31, 2027

Study Completion Date

December 31, 2028

Conditions

GI Cancers

Interventions

DRUG

7MW4911

study drug

All Listed Sponsors

lead

Mabwell (Shanghai) Bioscience Co., Ltd.

INDUSTRY